Clinical Trial Update: A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection [Phase 1]

View source ↗

Summary

A Phase I randomized, double-blind, placebo-controlled study evaluated the safety and immunogenicity of AERAS-404 with different antigen and adjuvant doses in H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• AERAS 404

Snippet

Sponsor: Aeras | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED